Energy metabolism in glioblastoma stem cells: PPARα a metabolic adaptor to intratumoral microenvironment.
Genre
Journal ArticleDate
2017-12-12Author
Fidoamore, AlessiaCristiano, Loredana
Laezza, Chiara
Galzio, Renato
Benedetti, Elisabetta
Cinque, Benedetta
Antonosante, Andrea
d'Angelo, Michele
Castelli, Vanessa
Cifone, Maria Grazia
Ippoliti, Rodolfo
Giordano, Antonio

Cimini, Annamaria
Permanent link to this record
http://hdl.handle.net/20.500.12613/4839
Metadata
Show full item recordDOI
10.18632/oncotarget.19086Abstract
Glioblastoma (GB), the most-common cancer in the adult brain, despite surgery and radio/ chemotherapy, is to date almost incurable. Many hypoxic tumors, including GB, show metabolic reprogramming to sustain uncontrolled proliferation, hypoxic conditions and angiogenesis. Peroxisome Proliferator-activated Receptors (PPAR), particularly the α isotype, have been involved in the control of energetic metabolism. Herein, we characterized patient-derived GB neurospheres focusing on their energetic metabolism and PPARα expression. Moreover, we used a specific PPARα antagonist and studied its effects on the energetic metabolism and cell proliferation/survival of GB stem cells. The results obtained demonstrate that tumor neurospheres are metabolically reprogrammed up-regulating glucose transporter, glucose uptake and glycogen and lipid storage, mainly under hypoxic culture conditions. Treatment with the PPARα antagonist GW6471 resulted in decreased cell proliferation and neurospheres formation. Therefore, PPARα antagonism arises as a potent new strategy as adjuvant to gold standard therapies for GB for counteracting recurrences and opening the way for pre-clinical trials for this class of compounds. When tumor neurospheres were grown in hypoxic conditions in the presence of different glucose concentrations, the most diluted one (0.25g/L) mimicking the real concentration present in the neurosphere core, PPARα increase/PPARγ decrease, increased proliferation and cholesterol content, decreased glycogen particles and LDs were observed. All these responses were reverted by the 72 h treatment with the PPARα antagonist.Has part
OncotargetADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/4821